For the Inventor, By the Inventor

Enter assignee name

Planegg/Martinsried, Germany

Medigene Ag

USPTO Granted Patents = 48

CIPO Patents = 8

EPO Patents = 20

Trademarks = 3

Forward Citations = 561

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Michael Hallek (21 out of 25 patents)

Christoph Bogedain (7 out of 8 patents)

Markus Hoerer (6 out of 6 patents)

4. Alexander Burger (6 out of 6 patents)

5. Ulrich Moebius (5 out of 7 patents)

6. Anne Girod (5 out of 5 patents)

7. Uwe Michaelis (4 out of 9 patents)

8. Yi Li (4 out of 23 patents)

9. Martin Ried (4 out of 4 patents)

10. Gerhard Maass (4 out of 5 patents)

11. Heinrich Haas (3 out of 20 patents)

12. Gerhard Winter (3 out of 36 patents)

13. Florian Sonntag (3 out of 3 patents)

14. Juergen Kleinschmidt (3 out of 3 patents)

15. Kerstin Lux (3 out of 3 patents)

Core Competencies:

Parvovirus Particles

Mutated Structural Proteins

Anti-HER2 Vaccine

Cationic Liposomal Preparation

Triple Receptor Negative Breast Cancer

Immunomodulating Compounds

Adeno-Associated Virus

Papillomavirus L1 Protein

Cytotoxic T-Cell Epitopes

Recombinant AAV Vector

Tumor Treatment

Viral Skin Diseases

48 patents: Sort by Forward Citations

1. 11267847 - Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 (2022-03-08),

2. 10822378 - Mutated structural protein of a parvovirus (2020-11-03),

3. 10408834 - Mutated parvovirus structural proteins as vaccines (2019-09-10),

4. 10344057 - Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 (2019-07-09),

5. 9821043 - Anti-HER2 vaccine based upon AAV derived multimeric structures (2017-11-21),

6. 9770406 - Medicament for the treatment of viral skin and tumour diseases (2017-09-26),

7. 9624274 - Mutated structural protein of a parvovirus (2017-04-18),

8. 9464119 - Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 (2016-10-11),

9. 9260521 - Treatment of tumors using specific anti-L1 antibody (2016-02-16),

10. 9238021 - Method of producing a cationic liposomal preparation comprising a lipophilic compound (2016-01-19),

11. 9233094 - Method of administering a cationic liposomal preparation (2016-01-12),

12. 9144563 - Treatment of triple receptor negative breast cancer (2015-09-29),

13. 9060998 - Use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin (2015-06-23),

14. 8663606 - Method of producing a cationic liposomal preparation comprising a lipophilic compound (2014-03-04),

15. 8580258 - Treatment of tumors using specific anti-L1 antibody (2013-11-12),

Medigene AG is a publicly listed biotechnology company headquartered in Germany. The company develops innovative immunotherapies to treat various types of cancer. They focus on the development of personalized T cell receptor (TCR) therapies and dendritic cell (DC) vaccines. Medigene also conducts preclinical and clinical research to further advance their therapeutic solutions. For more information, visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

48 Patents

#1 in Planegg/Martinsried

#1,136 in Germany

#14,122 in the World

Planegg/Martinsried, Germany

Medigene Ag

Forward Citations = 561

79 inventors:

Michael Hallek (21 out of 25 patents)

Christoph Bogedain (7 out of 8 patents)

Markus Hoerer (6 out of 6 patents)

4. Alexander Burger (6 out of 6 patents)

5. Ulrich Moebius (5 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…